Abstract 1590P
Background
International studies have highlighted the poor outcomes associated with cancer diagnosis following an emergency presentation (EP) to hospital. This study aims at assessing the rate of cancer patients newly referred to the Greater Paris University Hospitals (APHP) after an EP and the impact of EP on patient survival across various types of cancer.
Methods
A retrospective multicenter cohort study was conducted using the data warehouse of APHP. Consecutive patients newly referred with breast, lung, colon, rectum or pancreatic cancer between January 2019 and June 2022 were identified using claims data (ICD-10 codes). Comparative analyses between EP (diagnosis confirmed ≤30 days after emergency admission) and non-EP patients comprised in-hospital imaging, initial tumor staging from baseline PET/CT and CT-scan reports, and surgical treatment. Multivariable logistic regression was used to assess EP prevalence and its association with patient survival, adjusting for age, gender, diagnostic year (considering potential impacts of the COVID-19 pandemic), and cancer site. A Cox model was used to assess association of EP with survival, adjusting for the same factors and baseline metastatic status.
Results
The final cohort comprised 25,845 patients with 3,960 (15.3%) newly referred after an EP. EP patients exhibited higher rates of metastatic cancer (59% vs. 45%) and in-hospital imaging (53% vs. 31%), lower surgery rates (except for colon cancer patients) (18% vs 41%), and a higher risk to die within a year of diagnosis (49% vs 16%). Lung and pancreatic cancers were more frequent in EP than other cancer sites (20% and 23% respectively). The proportion of EP and non-EP patients was comparable during and after the COVID-19 pandemic, except for lung cancer. In the multivariable analysis, EP was strongly associated with age only for patients above 80 years of age (odds ratio: 3.1, 95% CI; 2.6-3.6). After adjusting for age and cancer site, patient mortality rate increased with EP referral (HR: 2.7, 95% CI 2.5-2.8).
Conclusions
Emergency presentation in a university hospital is a marker of poor outcome among newly referred cancer patients. Better coordination between hospitals and ambulatory health care networks is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1573P - Global cancer statistics for adolescents and young adults: New estimates from GLOBOCAN 2022
Presenter: Wang-Zhong Li
Session: Poster session 10
Resources:
Abstract
1574P - Medical oncology residents mentors (MORM): A target for resiliency interventions
Presenter: David Paez
Session: Poster session 10
1575P - Smoke-free policies in outdoor areas: A potential cancer prevention strategy in Spain
Presenter: Karen Ramírez Cervantes
Session: Poster session 10
1576P - Smoking and lung cancer mortality in Italian men and women: 2003-2019
Presenter: Diego Serraino
Session: Poster session 10
1577P - Indoor radon in patients with lung cancer in Spain: Preliminary data from the MIRROR study
Presenter: Marta Garcia De Herreros
Session: Poster session 10
1578P - Perception of LMIC oncologists on meaningful cancer trial endpoints and value of cancer drugs
Presenter: Soumitra Shankar Datta
Session: Poster session 10
1579P - The Dutch national adolescent and young adult (AYA) cancer care network, a data driven learning healthcare system
Presenter: Winette Van Der Graaf
Session: Poster session 10
1580P - Impact of social determinants of health (SDOH) on disparities in next-generation sequencing (NGS) testing in cancer patients (pts) in the US
Presenter: Chadi Hage Chehade
Session: Poster session 10
1581P - AI enabled intervention increased real-world guideline compliant care: Improving genomic testing and cascade genetics for women with ovarian cancer (OC)
Presenter: Premal Thaker
Session: Poster session 10
1582P - Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD)
Presenter: Lorena Incorvaia
Session: Poster session 10